Silexion Therapeutics collaborates with Catalent to develop RNAi therapies for KRAS-driven cancers
From GlobeNewswire: 2025-04-23 09:20:00 Silexion Therapeutics Corp. announced a collaboration with Catalent to develop RNAi therapies for KRAS-driven cancers. Catalent